Drug interactions with new and investigational antiretrovirals

Clinical Pharmacokinetics

Volumn 49, Issue 1, 2010, Pages 67-68

  Crauwels, Herta M ^a   Kakuda, Thomas N ^b  

^a TIBOTEC BVBA   (Belgium)

^b Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DIDANOSINE; ETRAVIRINE; FLUCONAZOLE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; RILPIVIRINE; RITONAVIR; TENOFOVIR DISOPROXIL;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; NITRILES; PYRIDAZINES; PYRIMIDINES;

EID: 72249096457     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11531240-000000000-00000     Document Type: Letter

References (12)

1. Brown KC, Paul S, Kashuba ADM. Drug interactions with new and in-vestigational antiretrovirals [published erratum appears in Clin Pharmaco-kinet 2009; 48: 554]. Clin Pharmacokinet 2009; 48: 211-241
2. Scholler-Gyure M, Woodfall B, De Marez T, et al. Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir [poster no. P278]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 12-16; Glasgow
3. Piscitelli S, Baede P, van t' Klooster G, et al. TMC125, a potent next generation NNRTI, does not alter lopinavir/ritonavir pharmacokinetics in healthy volunteers [poster no. A-1824]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego (CA)
4. Tibotec Pharmaceuticals, Ireland. TMC125-TiDP2-C238: an exploratory pharmacokinetics, safety and anti-HIV activity study of etravirine (ETR) when given with boosted atazanavir (ATV/Rtv) at two different doses and 1 nucleoside reverse transcriptase inhibitor (NRTI) in treatment experienced HIV patients [ClinicalTrials.gov identifier NCT00896051]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2009 Oct 2]
5. Scholler-Gyure M, Kakuda TN, Akuma SH, et al. Pharmacokinetic (PK) in-teraction between etravirine (ETR) and lopinavir/ritonavir (LPV/r) [abstract no. A1-1298]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12-15; San Francisco (CA)
6. Kakuda TN, Scholler-Gyure M, De Smedt G, et al. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Med 2009; 10: 173-181
7. Intelence™ (etravirine) tablets: US prescribing information. Raritan (NJ): Tibotec, Inc., 2008 Aug [online]. Available from URL: http://www. intelence-info.com/intelence/assets/pdf/INTELENCE-PI.pdf [Accessed 2009 Oct 2]
8. Intelence® (etravirine) tablets: summary of product characteristics. High Wycombe: Janssen-Cilag Ltd, 2009 May 14 [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/intelence/intelence. htm [Accessed 2009 Oct 19]
9. Scholler-Gyure M, Kakuda TN, van Solingen-Ristea R, et al. Pharmacokinetic (PK) interaction between etravirine (ETR) and fluconazole (FLU) or voriconazole (VOR) in HIV-negative volunteers [abstract no. A1-1299]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12-15; San Francisco (CA)
10. Tibotec Pharmaceuticals, Ireland. TMC278-TiDP6-C209: a clinical trial in treat-ment naive HIV-1 patients comparing TMC278 to efavirenz in combination with tenofovir + emtricitabine [ClinicalTrials.gov identifier NCT00540449]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Oct 2]
11. Tibotec Pharmaceuticals, Ireland. TMC278-TiDP6-C215: a clinical trial in treatment naive HIV-subjects patients comparing TMC278 to efavirenz in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors [ClinicalTrials.gov identifier NCT00543725]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials. gov [Accessed 2009 Oct 2]
12. Hoetelmans R, van Heeswijk R, Kestens D, et al. Pharmacokinetic interaction between TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) and lopinavir/ritonavir (LPV/r) in healthy volunteers [abstract no. PE4.3/1]. 10th European AIDS Conference; 2005 Nov 17-20; Dublin